Advancing glioblastoma treatment: Akeso and INOVIO's collaboration on innovative therapies
In an exciting development in the fight against glioblastoma (GBM), one of the most aggressive forms of brain cancer, Akeso, Inc. and INOVIO have announced a clinical collaboration to explore a novel combination therapy. This partnership aims to evaluate the efficacy of Akeso's cadonilimab, a first-in-class bispecific antibody targeting PD-1/CTLA-4, when combined with INOVIO's investigational DNA immunotherapy, INO-5412, which consists of INO-5401 plus INO-9012. This study is a critical component of the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute.
The INSIGhT trial is designed as a Phase II adaptive platform trial, which allows for the rapid assessment of new treatments for GBM. This innovative trial format enables researchers to adapt the study based on preliminary results, thereby expediting the discovery of effective therapies for this particularly challenging cancer. Dosage for the combination therapy is set to commence in the latter half of 2026, marking a significant step towards exploring various therapeutic options for GBM patients.
Cadonilimab has previously gained traction in China, receiving marketing approval for several indications, including gastric and cervical cancers. Known for its unique mechanism as a bispecific antibody, cadonilimab acts on both PD-1 and CTLA-4, providing enhanced checkpoint inhibition. Its clinical efficacy has been substantiated through multiple Phase III trials, demonstrating promising results across different cancer types. By integrating cadonilimab with INO-5412, the collaboration aims to leverage its immunological benefits to enhance patient responses against GBM.
INO-5412 represents the combination of INO-5401, which targets several tumor antigens, and the immune activator INO-9012. This investigational therapy has shown robust immune responses in ongoing Phase II trials for newly diagnosed GBM patients, showcasing noteworthy correlations between treatment and patient survival outcomes. By combining this targeted approach with cadonilimab, the collaboration seeks to push the boundaries of current therapeutic interventions for glioblastoma.
Dr. David Reardon from Dana-Farber Cancer Institute stated, "The INSIGhT trial was designed to help quickly advance cutting-edge treatments for GBM, the most common and aggressive form of brain cancer for which there are few effective treatments currently available or in development. We are excited to include INOVIO and Akeso's novel combination immunotherapy in the trial and welcome their efforts to help improve potential outcomes for patients."
Yu (Michelle) Xia, CEO of Akeso, expressed enthusiasm for the collaboration, stating that they are committed to pushing boundaries with cadonilimab through a global partnership strategy. She emphasized the importance of advancing this promising combination approach to tackle GBM more effectively.
This collaborative effort between Akeso and INOVIO represents a significant advancement in cancer immunotherapy research, offering hope for improved treatment pathways for glioblastoma patients. Both companies are dedicated to driving innovative solutions to address cancer, exemplified by their combined expertise and pioneering approaches. As the trial approaches its commencement, the medical community eagerly anticipates the results that may redefine treatment options for glioblastoma, potentially enhancing survival rates for affected patients.
The Importance of the INSIGhT Trial
The INSIGhT trial is designed as a Phase II adaptive platform trial, which allows for the rapid assessment of new treatments for GBM. This innovative trial format enables researchers to adapt the study based on preliminary results, thereby expediting the discovery of effective therapies for this particularly challenging cancer. Dosage for the combination therapy is set to commence in the latter half of 2026, marking a significant step towards exploring various therapeutic options for GBM patients.
Cadonilimab: A Promising Immunotherapy
Cadonilimab has previously gained traction in China, receiving marketing approval for several indications, including gastric and cervical cancers. Known for its unique mechanism as a bispecific antibody, cadonilimab acts on both PD-1 and CTLA-4, providing enhanced checkpoint inhibition. Its clinical efficacy has been substantiated through multiple Phase III trials, demonstrating promising results across different cancer types. By integrating cadonilimab with INO-5412, the collaboration aims to leverage its immunological benefits to enhance patient responses against GBM.
INO-5412: A Potential Game-Changer
INO-5412 represents the combination of INO-5401, which targets several tumor antigens, and the immune activator INO-9012. This investigational therapy has shown robust immune responses in ongoing Phase II trials for newly diagnosed GBM patients, showcasing noteworthy correlations between treatment and patient survival outcomes. By combining this targeted approach with cadonilimab, the collaboration seeks to push the boundaries of current therapeutic interventions for glioblastoma.
Statements from Leaders in the Field
Dr. David Reardon from Dana-Farber Cancer Institute stated, "The INSIGhT trial was designed to help quickly advance cutting-edge treatments for GBM, the most common and aggressive form of brain cancer for which there are few effective treatments currently available or in development. We are excited to include INOVIO and Akeso's novel combination immunotherapy in the trial and welcome their efforts to help improve potential outcomes for patients."
Yu (Michelle) Xia, CEO of Akeso, expressed enthusiasm for the collaboration, stating that they are committed to pushing boundaries with cadonilimab through a global partnership strategy. She emphasized the importance of advancing this promising combination approach to tackle GBM more effectively.
Looking Ahead
This collaborative effort between Akeso and INOVIO represents a significant advancement in cancer immunotherapy research, offering hope for improved treatment pathways for glioblastoma patients. Both companies are dedicated to driving innovative solutions to address cancer, exemplified by their combined expertise and pioneering approaches. As the trial approaches its commencement, the medical community eagerly anticipates the results that may redefine treatment options for glioblastoma, potentially enhancing survival rates for affected patients.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.